AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03935204 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine,270μg/1.0ml
Description: HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
Study NCT03935204 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aluminium adjuvant (1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
Study NCT02893943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Study NCT02893943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02040506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGN523
Description: Given intravenously every week for 8 weeks. Dosing beyond 8 weeks will be permitted for subjects meeting criteria for ongoing clinical benefit and acceptable safety.
Study NCT04066595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 60 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
Study NCT02906358 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community-based pain self-management
Study NCT02906358 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic-based pain self-management
Study NCT02202070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Study NCT01363024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MFGR1877S
Description: Intravenous escalating dose
Study NCT03323047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Oral acetaminophen (15 mg/kg) 1 hr pre-operatively
Study NCT03323047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Oral acetaminophen (15 mg/kg) 1 hr pre-operatively
Study NCT03323047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose Dexamethasone
Description: Intravenous low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
Study NCT03323047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose Dexamethasone
Description: Intravenous low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
Study NCT03323047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Oral placebo 1 hr pre-operatively
Study NCT03323047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose Dexamethasone
Description: Intravenous high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia
Study NCT03958253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toolbox for Lung Cancer Screening
Description: -Toolbox of evidence-based elements that a primary care or referral site could implement to address known barriers to screening and referral, as well as required elements for screening. These elements will be designed to be adaptable to the unique needs and screening processes of the participating practices.~* Patient education materials~* Primary care practice educational materials~* Pack-years/eligibility calculator~* Local referral process guide~* Smoking cessation materials and support~* Shared decision-making guide~* LDCT best practice guidelines
Study NCT00577395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral tablet once a month for 12 months
Study NCT00577395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: tablet, 150 mg once a month for 12 months
Study NCT04232280 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
Study NCT04232280 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study NCT01327508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRIGEN SURESHOT Distal Targeting Instrumentation.
Description: image-guided localization system
Study NCT01327508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free-hand technique
Description: Free-hand technique utilizes x-rays to find screw holes.
Study NCT01344304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant / Fosaprepitant
Description: Aprepitant:~125 mg PO on day 1 80 mg PO on days 2 to 3~Fosaprepitant:~150 mg IV on day 1
Study NCT02237001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suture-based meniscal repair
Description: Suture-based meniscal repair
Study NCT00416494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10 mg/kg intravenously over 30-90 minutes on day 1
Study NCT00416494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/m2 intravenously over 2 hours on day 1.
Study NCT00416494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
Study NCT00416494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort
Study NCT03567967 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fruit and vegetable voucher
Description: Participants will receive four vouchers, each dated for a month, to be used on fruits and vegetables at specified local corner stores, supermarkets, and farmer's markets for a duration of six months. Each study participant will have the same intervention, as this is a non-inferiority trial to compare voucher use in LA and test whether the nutritional effects of that use are non-inferior to use in SF.
Study NCT03567967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable voucher
Description: Participants will receive four vouchers, each dated for a month, to be used on fruits and vegetables at specified local corner stores, supermarkets, and farmer's markets for a duration of six months. Each study participant will have the same intervention, as this is a non-inferiority trial to compare voucher use in LA and test whether the nutritional effects of that use are non-inferior to use in SF.
Study NCT01887730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand washing with soap and water
Description: Can infections be prevented by hand washing with soap and water
Study NCT01887730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand cleaning with alcohol-containing hand rub
Description: Can infections be prevented by hand cleaning with alcohol-containing hand rub. Effect of intervention is assessed by following occurrence of infections
Study NCT01887730 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study NCT01746355 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Patients undergoing of repetitive transcranial magnetic stimulation for treatment of AFP.
Study NCT01746355 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Patients undergoing of repetitive transcranial magnetic stimulation for treatment of AFP.
Study NCT01297608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caoted suppository
Description: coated suppository with active drug
Study NCT01297608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: coated suppository
Description: coated suppository with placebo
Study NCT01297608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: coated suppository
Description: coated suppository with placebo
Study NCT01091714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: Approximately 2400 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
Study NCT01091714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: Approximately 2240 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
Study NCT01091714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: Approximately 2332 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
Study NCT03272386 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Completing a questionnaire
Study NCT06431672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interpersonal group psychotherapy
Description: Interpersonal psychotherapy (IPT) was developed by Stuart and O'Hara (1995). It addresses four domains of conflict. The intervention is an eight-session P-IPTG, which consisted of four sessions in pregnancy and four in postpartum.
Study NCT02427022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CTI
Description: CTI is an empirically supported, time-limited case management model designed to prevent homelessness and other adverse outcomes in people with mental illness following discharge from hospitals, shelters, prisons and other institutions. CTI was originally developed and tested by researchers and clinicians at Columbia University and New York State Psychiatric Institute with significant support from the National Institute of Mental Health and the New York State Office of Mental Health.
Study NCT02427022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTI
Description: CTI is an empirically supported, time-limited case management model designed to prevent homelessness and other adverse outcomes in people with mental illness following discharge from hospitals, shelters, prisons and other institutions. CTI was originally developed and tested by researchers and clinicians at Columbia University and New York State Psychiatric Institute with significant support from the National Institute of Mental Health and the New York State Office of Mental Health.
Study NCT00708968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOCUS Program
Description: Supportive, educative sessions with patients and spouses.
Study NCT02447042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid challenge with crystalloids
Description: Intravenous infusion of 2, 3, 4 or 5 ml/Kg of crystalloids over 5 minutes.
Study NCT00655122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin sodium
Description: Dalteparin sodium was administered at a daily dosage of 5,000 UI anti-Xa by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
Study NCT00655122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered with a daily injection of 0.2 mL by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
Study NCT01626755 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic name block
Description: Ultrasound-guided sciatic nerve block.
Study NCT01626755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic name block
Description: Ultrasound-guided sciatic nerve block.
Study NCT00342628 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-rEPA conjugate vaccine for typhoid fever
Description: Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.
Study NCT00342628 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib-TT
Description: Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid
Study NCT00342628 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP
Description: DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
Study NCT04378738 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: survey
Description: all people in the cohort
Study NCT04463797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Square-stepping exercise
Description: The square-stepping exercise is a low-cost indoor program to improve lower extremities fitness and cognitive function.
Study NCT04463797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching and strengthening
Description: whole-body stretching and upper extremity strengthening
Study NCT01307176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: The home exercise program uses standard physical therapy exercises that have never been rigorously tested for people with cerebellar ataxia. These include sitting balance exercises (e.g. sitting on a peanut-shaped exercise ball and moving arms or legs), standing balance exercises (e.g. weight shifting, moving arms and legs), and walking exercises (e.g. walking heel-to-toe). The exercises are in a progression, going from less to more challenging. Though the exercises are standard, they are the intervention that we are testing and we will consider them experimental.
Study NCT06027385 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: molecular-based screening
Description: Test for three mutations in the CTNS gene and one mutation in the SMA1 gene.
Study NCT00624442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 1.0 mg/kg/h followed by 23 hours at 0.1 mg/kg/h
Study NCT03054415 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopy
Description: colonic biopsies during endoscopy and anal manometry with barostat and anal endoflip
Study NCT01074294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPDC-34712
Description: OPDC-34712 tablets, daily, Orally.
Study NCT01074294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching-placebo tablets, daily, Orally.
Study NCT02361242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT00864
Description: PXT00864 is a fixed-dose combination of baclofen and acamprosate
Study NCT01074294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching-placebo tablets, daily, Orally.
Study NCT01074294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stimulant Therapy
Description: Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.
Study NCT01074294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stimulant Therapy
Description: Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.
Study NCT02831231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: xanomeline tartrate
Description: xanomeline tartrate, 75 mg capsule, TID
Study NCT04569669 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FFR and FFRCT
Description: All the patients will undergo computed coronary tomography angiography to analysis FFRCT . Then FFR will be measured during invasive cardiac catheterization.
Study NCT04187417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical tetracaine hydrochloride 1%
Description: topical ophthalmologic anesthestic
Study NCT04187417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01773837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: methylphenidate (pill) p.o. 15 to 25 mg daily for six days
Study NCT01773837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (pill) p.o.
Study NCT02831231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xanomeline tartrate
Description: xanomeline tartrate, 75 mg capsule, TID
Study NCT02831231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trospium chloride
Description: trospium chloride, over encapsulated 20 mg tablet, BID
Study NCT01250769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Toothbrush
Description: A standard size manual toothbrush to clean visible tooth surfaces
Study NCT01250769 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Toothbrush
Description: A standard size manual toothbrush to clean visible tooth surfaces
Study NCT01250769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interproximal Cleaning Device
Description: An electronic device that combines water and air to clean between the teeth
Study NCT01286064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Fluoroscopy
Description: Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
Study NCT01286064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Fluoroscopy
Description: Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
Study NCT03103048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Without bandages
Description: All volunteers will be held the grasping force measurements without application of elastic adhesive bandage or micropore
Study NCT03103048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Without bandages
Description: All volunteers will be held the grasping force measurements without application of elastic adhesive bandage or micropore
Study NCT03103048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: With placebo
Description: All volunteers will be held the grasping force measurements with application of micropore (placebo) on his forearm in both upper members
Study NCT03103048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: With placebo
Description: All volunteers will be held the grasping force measurements with application of micropore (placebo) on his forearm in both upper members
Study NCT03103048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: With bandage
Description: All volunteers will be held the grasping force measurements with application of bandage without tension in the forearm in both upper members
Study NCT03103048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: With bandage
Description: All volunteers will be held the grasping force measurements with application of bandage without tension in the forearm in both upper members
Study NCT02950818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take Heart
Description: Participants receive an evidence-based heart disease self management program consisting of a combination of five two and a half hour group sessions and telephone counseling offered by a trained facilitator employed by the Detroit Area Agency on Aging. The program is designed so that participants select an area to work on (e.g., diet, exercise, medication taking, communication with health care professionals) and receive support, information, and encouragement from group members and program facilitators, to help them reach their goals.
Study NCT01205984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Patients enrolled in the study were given either oral amoxicillin/clavulanate (AMX/C) or metylprednisolone (MP) (group MP) or AMX/C and placebo (group P) twice daily using a random allocation chart based on a table of random numbers. Oral AMX/C was administered 45/6.4 mg/kg/d (maximum 2000/285 mg/d) for 30 days for both groups. Oral MP was administered for the first 15 days: 1 mg/kg/d (maximum 40 mg/d) for 10 days, 0.75 mg/kg/d for 2 days, 0.5 mg/kg/d for 2 days, and 0.25 mg/kg/d for 1 day. Placebo tablets contained lactose and were of same size and color as MP tablets.